Ovarian clear cell carcinoma as a stress-responsive cancer: Influence of the microenvironment on the carcinogenesis and cancer phenotype

Cancer Letters

Volumn 310, Issue 2, 2011, Pages 129-133

  Mandai, Masaki ^a   Matsumura, Noriomi ^a   Baba, Tsukasa ^a   Yamaguchi, Ken ^a   Hamanishi, Junzo ^a   Konishi, Ikuo ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Clear cell carcinoma; Endometriosis; Microarray; Microenvironment; Ovarian cancer; Oxidative stress; Pathogenesis

Indexed keywords

BEVACIZUMAB; EVEROLIMUS; GAMMA INTERFERON; HEPATOCYTE NUCLEAR FACTOR 1BETA; INTERLEUKIN 2; IRON; MITOGEN ACTIVATED PROTEIN KINASE; REACTIVE OXYGEN METABOLITE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN;

CANCER RESISTANCE; CARCINOGENESIS; CLEAR CELL CARCINOMA; DNA DAMAGE; ENDOMETRIOSIS; GENE EXPRESSION; HUMAN; KIDNEY CARCINOMA; MALIGNANT TRANSFORMATION; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; NONHUMAN; OVARIAN CLEAR CELL CARCINOMA; OVARY CANCER; OXIDATIVE STRESS; PRIORITY JOURNAL; SHORT SURVEY; TUMOR MICROENVIRONMENT;

EID: 80051696232     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.06.039     Document Type: Review

References (35)

1. Bulun S.E. Endometriosis. New Engl. J. Med. 2009, 360(3):268-279.
2. Kobayashi H., Sumimoto K., Moniwa N., Imai M., Takakura K., Kuromaki T., Morioka E., Arisawa K., Terao T. Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan. Int. J. Gynecol. Cancer 2007, 17(1):37-43.
3. McMeekin D.S., Burger R.A., Manetta A., DiSaia P., Berman M.L. Endometrioid adenocarcinoma of the ovary and its relationship to endometriosis. Gynecol. Oncol. 1995, 59(1):81-86.
4. Komiyama S., Aoki D., Tominaga E., Susumu N., Udagawa Y., Nozawa S. Prognosis of Japanese patients with ovarian clear cell carcinoma associated with pelvic endometriosis: clinicopathologic evaluation. Gynecol. Oncol. 1999, 72(3):342-346.
5. Mandai M., Yamaguchi K., Matsumura N., Baba T., Konishi I. Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management. Int. J. Clin. Oncol. 2009, 14(5):383-391.
6. Kato N., Sasou S., Motoyama T. Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod. Pathol. 2006, 19(1):83-89.
7. Wiegand K.C., Shah S.P., Al-Agha O.M., Zhao Y., Tse K., Zeng T., Senz J., McConechy M.K., Anglesio M.S., Kalloger S.E., Yang W., Heravi-Moussavi A., Giuliany R., Chow C., Fee J., Zayed A., Prentice L., Melnyk N., Turashvili G., Delaney A.D., Madore J., Yip S., McPherson A.W., Ha G., Bell L., Fereday S., Tam A., Galletta L., Tonin P.N., Provencher D., Miller D., Jones S.J., Moore R.A., Morin G.B., Oloumi A., Boyd N., Aparicio S.A., Shih I.e.M., Mes-Masson A.M., Bowtell D.D., Hirst M., Gilks B., Marra M.A., Huntsman D.G. ARID1A mutations in endometriosis-associated ovarian carcinomas. New Engl. J. Med. 2010, 363(16):1532-1543.
8. Whiteside T.L. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008, 27(45):5904-5912.
9. Laconi E. The evolving concept of tumor microenvironments. Bioessays 2007, 29(8):738-744.
10. Yamaguchi K., Mandai M., Toyokuni S., Hamanishi J., Higuchi T., Takakura K., Fujii S. Contents of endometriotic cysts, especially the high concentration of free iron, are a possible cause of carcinogenesis in the cysts through the iron-induced persistent oxidative stress. Clin. Cancer Res. 2008, 14(1):32-40.
11. Iizuka M., Igarashi M., Abe Y., Ibuki Y., Koyasu Y., Ikuma K. Chemical assay of iron in ovarian cysts: a new diagnostic method to evaluate endometriotic cysts. Gynecol. Obstet. Invest. 1998, 46(1):58-60.
12. Takahashi K., Okada S., Okada M., Kitao M., Kaji Y., Sugimura K. Magnetic resonance relaxation time in evaluating the cyst fluid characteristics of endometrioma. Hum. Reprod. 1996, 11(4):857-860.
13. Adachi S., Yoshida S., Kawamura K., Takahashi M., Uchida H., Odagiri Y., Takemoto K. Inductions of oxidative DNA damage and mesothelioma by crocidolite, with special reference to the presence of iron inside and outside of asbestos fiber. Carcinogenesis 1994, 15(4):753-758.
14. Toyokuni S. Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci. 2009, 100(1):9-16.
15. Toyokuni S., Tanaka T., Nishiyama Y., Okamoto K., Nakashima Y., Hamazaki S., Okada S., Hiai H. Induction of renal cell carcinoma in male Wistar rats treated with cupric nitrilotriacetate. Lab. Invest. 1996, 75(2):239-248.
16. Körner M., Burckhardt E., Mazzucchelli L. Higher frequency of chromosomal aberrations in ovarian endometriosis compared to extragonadal endometriosis: a possible link to endometrioid adenocarcinoma. Mod. Pathol. 2006, 19(12):1615-1623.
17. Melin A., Sparén P., Persson I., Bergqvist A. Endometriosis and the risk of cancer with special emphasis on ovarian cancer. Hum. Reprod. 2006, 21(5):1237-1242.
18. Coquelle A., Toledo F., Stern S., Bieth A., Debatisse M. A new role for hypoxia in tumor progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs. Mol. Cell 1998, 2(2):259-265.
19. Meng A.X., Jalali F., Cuddihy A., Chan N., Bindra R.S., Glazer P.M., Bristow R.G. Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiother. Oncol. 2005, 76(2):168-176.
20. Gates M.A., Rosner B.A., Hecht J.L., Tworoger S.S. Risk factors for epithelial ovarian cancer by histologic subtype. Am. J. Epidemiol. 2010, 171(1):45-53.
21. Yamaguchi K., Mandai M., Oura T., Matsumura N., Hamanishi J., Baba T., Matsui S., Murphy S.K., Konishi I. Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene 2010, 29(12):1741-1752.
22. Gonda T.A., Tu S., Wang T.C. Chronic inflammation, the tumor microenvironment and carcinogenesis. Cell Cycle 2009, 8(13):2005-2013.
23. Matsumura N., Mandai M., Okamoto T., Yamaguchi K., Yamamura S., Oura T., Baba T., Hamanishi J., Kang H.S., Matsui S., Mori S., Murphy S.K., Konishi I. Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. Cancer Sci. 2010, 101(12):2658-2663.
24. McDermott D.F., Atkins M.B. Application of IL-2 and other cytokines in renal cancer. Expert Opin. Biol. Ther. 2004, 4(4):455-468.
25. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Staehler M., Negrier S., Chevreau C., Desai A.A., Rolland F., Demkow T., Hutson T.E., Gore M., Anderson S., Hofilena G., Shan M., Pena C., Lathia C., Bukowski R.M. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol. 2009, 27(20):3312-3318.
26. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Oudard S., Negrier S., Szczylik C., Pili R., Bjarnason G.A., Garcia-del-Muro X., Sosman J.A., Solska E., Wilding G., Thompson J.A., Kim S.T., Chen I., Huang X., Figlin R.A. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2009, 27(22):3584-3590.
27. Patel P.H., Chadalavada R.S., Chaganti R.S., Motzer R.J. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin. Cancer Res. 2006, 12(24):7215-7220.
28. Wilhelm S., Carter C., Lynch M., Lowinger T., Dumas J., Smith R.A., Schwartz B., Simantov R., Kelley S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 2006, 5(10):835-844.
29. Liu L., Cao Y., Chen C., Zhang X., McNabola A., Wilkie D., Wilhelm S., Lynch M., Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006, 66(24):11851-11858.
30. Keswani R.N., Chumsangsri A., Mustafi R., Delgado J., Cohen E.E., Bissonnette M. Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line. Dis. Esophagus 2008, 21(6):514-521.
31. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., Staroslawska E., Sosman J., McDermott D., Bodrogi I., Kovacevic Z., Lesovoy V., Schmidt-Wolf I.G., Barbarash O., Gokmen E., O'Toole T., Lustgarten S., Moore L., Motzer R.J., Global ARCC Trial Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New Engl. J. Med. 2007, 356(22):2271-2281.
32. Motzer R.J., Escudier B., Oudard S., Hutson T.E., Porta C., Bracarda S., Grünwald V., Thompson J.A., Figlin R.A., Hollaender N., Urbanowitz G., Berg W.J., Kay A., Lebwohl D., Ravaud A., RECORD-1 Study Group Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372(9637):449-456.
33. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., Steinberg S.M., Chen H.X., Rosenberg S.A. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. New Engl. J. Med. 2003, 349(5):427-434.
34. Clark P.E. The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Kidney Int. 2009, 76(9):939-945.
35. Tsuchiya A., Sakamoto M., Yasuda J., Chuma M., Ohta T., Ohki M., Yasugi T., Taketani Y., Hirohashi S. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am. J. Pathol. 2003, 163(6):2503-2512.